Vertex Pharmaceuticals recently announced its largest-ever acquisition.
The drugmaker is paying up for a new growth engine. Is the price disciplined?
This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.
Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...
The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder ...
Vertex AI is a comprehensive machine learning platform by Google Cloud, provides an all-inclusive suite of tools and resources for the creation, deployment, and customization of machine learning ...